vs

Side-by-side financial comparison of PUMA BIOTECHNOLOGY, INC. (PBYI) and TXO Partners, L.P. (TXO). Click either name above to swap in a different company.

TXO Partners, L.P. is the larger business by last-quarter revenue ($103.7M vs $75.5M, roughly 1.4× PUMA BIOTECHNOLOGY, INC.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs 14.5%). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 23.1%).

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

TXO Partners, L.P. is a U.S.-based energy sector master limited partnership. It acquires, develops and manages oil and natural gas assets across key North American production basins, with operations covering upstream exploration, production and midstream transportation, serving industrial, utility and wholesale energy clients.

PBYI vs TXO — Head-to-Head

Bigger by revenue
TXO
TXO
1.4× larger
TXO
$103.7M
$75.5M
PBYI
Growing faster (revenue YoY)
PBYI
PBYI
+13.3% gap
PBYI
27.7%
14.5%
TXO
Faster 2-yr revenue CAGR
PBYI
PBYI
Annualised
PBYI
31.3%
23.1%
TXO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PBYI
PBYI
TXO
TXO
Revenue
$75.5M
$103.7M
Net Profit
$-28.3M
Gross Margin
69.3%
Operating Margin
22.7%
-26.1%
Net Margin
-27.2%
Revenue YoY
27.7%
14.5%
Net Profit YoY
-376.5%
EPS (diluted)
$0.26
$-0.57

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PBYI
PBYI
TXO
TXO
Q4 25
$75.5M
$103.7M
Q3 25
$54.5M
$90.6M
Q2 25
$52.4M
$75.0M
Q1 25
$46.0M
$93.8M
Q4 24
$59.1M
$90.6M
Q3 24
$80.5M
$69.3M
Q2 24
$47.1M
$57.0M
Q1 24
$43.8M
$68.5M
Net Profit
PBYI
PBYI
TXO
TXO
Q4 25
$-28.3M
Q3 25
$8.8M
$4.4M
Q2 25
$5.9M
$-135.0K
Q1 25
$3.0M
$2.4M
Q4 24
$10.2M
Q3 24
$20.3M
$203.0K
Q2 24
$-4.5M
$2.8M
Q1 24
$-4.8M
$10.3M
Gross Margin
PBYI
PBYI
TXO
TXO
Q4 25
69.3%
Q3 25
77.7%
Q2 25
76.5%
Q1 25
77.1%
Q4 24
76.4%
Q3 24
63.9%
Q2 24
77.4%
Q1 24
75.5%
Operating Margin
PBYI
PBYI
TXO
TXO
Q4 25
22.7%
-26.1%
Q3 25
17.6%
4.2%
Q2 25
12.7%
-5.0%
Q1 25
8.7%
-3.8%
Q4 24
22.6%
6.1%
Q3 24
27.4%
-7.2%
Q2 24
-4.6%
-17.7%
Q1 24
-5.3%
3.9%
Net Margin
PBYI
PBYI
TXO
TXO
Q4 25
-27.2%
Q3 25
16.2%
4.8%
Q2 25
11.2%
-0.2%
Q1 25
6.5%
2.6%
Q4 24
11.3%
Q3 24
25.2%
0.3%
Q2 24
-9.6%
4.9%
Q1 24
-11.0%
15.0%
EPS (diluted)
PBYI
PBYI
TXO
TXO
Q4 25
$0.26
$-0.57
Q3 25
$0.17
$0.08
Q2 25
$0.12
$0.00
Q1 25
$0.06
$0.06
Q4 24
$0.40
$0.22
Q3 24
$0.41
$0.01
Q2 24
$-0.09
$0.09
Q1 24
$-0.10
$0.33

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PBYI
PBYI
TXO
TXO
Cash + ST InvestmentsLiquidity on hand
$97.5M
$9.4M
Total DebtLower is stronger
$22.7M
$291.1M
Stockholders' EquityBook value
$130.3M
Total Assets
$216.3M
$1.4B
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PBYI
PBYI
TXO
TXO
Q4 25
$97.5M
$9.4M
Q3 25
$94.4M
$5.3M
Q2 25
$96.0M
$8.0M
Q1 25
$93.2M
$10.8M
Q4 24
$101.0M
$7.3M
Q3 24
$96.7M
$3.8M
Q2 24
$96.8M
$76.0M
Q1 24
$107.2M
$4.6M
Total Debt
PBYI
PBYI
TXO
TXO
Q4 25
$22.7M
$291.1M
Q3 25
$34.0M
$271.1M
Q2 25
$45.3M
$19.1M
Q1 25
$56.7M
$162.1M
Q4 24
$68.0M
$157.1M
Q3 24
$79.3M
$155.1M
Q2 24
$90.7M
$7.1M
Q1 24
$102.0M
$26.1M
Stockholders' Equity
PBYI
PBYI
TXO
TXO
Q4 25
$130.3M
Q3 25
$115.3M
Q2 25
$104.7M
Q1 25
$97.1M
Q4 24
$92.1M
Q3 24
$71.1M
Q2 24
$48.5M
Q1 24
$51.0M
Total Assets
PBYI
PBYI
TXO
TXO
Q4 25
$216.3M
$1.4B
Q3 25
$202.9M
$1.4B
Q2 25
$194.9M
$1.0B
Q1 25
$196.2M
$1.0B
Q4 24
$213.3M
$1.0B
Q3 24
$220.7M
$1.0B
Q2 24
$205.0M
$774.5M
Q1 24
$214.1M
$688.2M
Debt / Equity
PBYI
PBYI
TXO
TXO
Q4 25
0.17×
Q3 25
0.30×
Q2 25
0.43×
Q1 25
0.58×
Q4 24
0.74×
Q3 24
1.12×
Q2 24
1.87×
Q1 24
2.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PBYI
PBYI
TXO
TXO
Operating Cash FlowLast quarter
$14.4M
$32.5M
Free Cash FlowOCF − Capex
$14.4M
FCF MarginFCF / Revenue
19.1%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$41.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PBYI
PBYI
TXO
TXO
Q4 25
$14.4M
$32.5M
Q3 25
$9.7M
$28.3M
Q2 25
$14.1M
$26.9M
Q1 25
$3.6M
$30.6M
Q4 24
$15.6M
$40.5M
Q3 24
$11.0M
$20.7M
Q2 24
$1.0M
$22.9M
Q1 24
$11.2M
$25.2M
Free Cash Flow
PBYI
PBYI
TXO
TXO
Q4 25
$14.4M
Q3 25
$9.7M
Q2 25
$14.1M
Q1 25
$3.6M
Q4 24
$15.6M
Q3 24
$11.0M
Q2 24
$1.0M
Q1 24
FCF Margin
PBYI
PBYI
TXO
TXO
Q4 25
19.1%
Q3 25
17.7%
Q2 25
26.8%
Q1 25
7.7%
Q4 24
26.4%
Q3 24
13.7%
Q2 24
2.1%
Q1 24
Capex Intensity
PBYI
PBYI
TXO
TXO
Q4 25
0.0%
Q3 25
0.0%
Q2 25
0.0%
Q1 25
0.1%
Q4 24
0.0%
Q3 24
0.0%
Q2 24
0.0%
Q1 24
0.0%
Cash Conversion
PBYI
PBYI
TXO
TXO
Q4 25
Q3 25
1.10×
6.50×
Q2 25
2.41×
Q1 25
1.21×
12.67×
Q4 24
3.96×
Q3 24
0.54×
102.02×
Q2 24
8.15×
Q1 24
2.45×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PBYI
PBYI

Segment breakdown not available.

TXO
TXO

Oil And Condensate$92.8M89%
Natural Gas Liquids Reserves$8.2M8%
Other$2.8M3%

Related Comparisons